pregabalin in childhood eoilepsy

pregabalin in childhood epilepsy: clinical trial in qom and tehran

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014012216320N1

Enrollment

Registered

2014-05-23

Start date

2014-05-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Seizure. Attack with loss of consciousness

Interventions

Pregabalin used as add on therapy in childhood epilepsy.cap.25-50-75-100-150 mg.10mg/kg/day.2-3 time/day..

Treatment - Drugs

Pregabalin used as add on therapy in childhood epilepsy.cap.25-50-75-100-150 mg.10mg/kg/day.2-3 time/day.

Eligibility

Sex/Gender

All

Age

11 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion critria: all patients with refractory seizure Exclusion criteria: patients with myoclonic siezures; sensitivty to PGB; patients that recieved gabapentin.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Decrease count of seizure. Timepoint: One and four mounth after intervention. Method of measurement: Counting.;Decrease intensity of seizure. Timepoint: One and four month after intervention. Method of measurement: Asking from parents.	—

Secondary

Measure	Time frame
Drug reaction. Timepoint: One and four month after interventionque. Method of measurement: Quetionair.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohsen molla mohammadi

Qom medical university

dr.mmohamadi@muq.ac.ir+98 25 3665 1802

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026